Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT). Issue 5 (22nd May 2019)

• Record Type: Journal Article
• Authors: Lyttle, Mark D; Bielicki, Julia A; Barratt, Sam; Dunn, David; Finn, Adam; Harper, Lynda; Jackson, Pauline; Powell, Colin V E; Roland, Damian; Stohr, Wolfgang; Sturgeon, Kate; Wan, Mandy; Little, Paul; Faust, Saul N; Robotham, Julie; Hay, Alastair D; Gibb, Diana M; Sharland, Mike
• Is Part Of: BMJ open. Volume 9:Issue 5(2019)
• Publication Date: 2019-05-22
• Subjects: community-acquired pneumonia -- antimicrobial resistance; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-029875
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Community-acquired pneumonia (CAP) is a common indication for antibiotic treatment in young children. Data are limited regarding the ideal dose and duration of amoxicillin, leading to practice variation which may impact on treatment failure and antimicrobial resistance (AMR). Community-Acquired Pneumonia: a randomIsed controlled Trial (CAP-IT) aims to determine the optimal amoxicillin treatment strategies for CAP in young children in relation to efficacy and AMR. Methods and analysis: The CAP-IT trial is a multicentre, randomised, double-blind, placebo-controlled 2×2 factorial non-inferiority trial of amoxicillin dose and duration. Children are enrolled in paediatric emergency and inpatient environments, and randomised to receive amoxicillin 70–90 or 35–50 mg/kg/day for 3 or 7 days following hospital discharge. The primary outcome is systemic antibacterial treatment for respiratory tract infection (including CAP) other than trial medication up to 4 weeks after randomisation. Secondary outcomes include adverse events, severity and duration of parent-reported CAP symptoms, adherence and antibiotic resistance. The primary analysis will be by intention to treat. Assuming a 15% primary outcome event rate, 8% non-inferiority margin assessed against an upper one-sided 95% CI, 90% power and 15% loss to follow-up, 800 children will be enrolled to demonstrate non-inferiority for the primary outcome for each of duration and dose. Ethics and dissemination: The CAP-IT trial and relevant materials were approved by the National Research Ethics Service (reference: 16/LO/0831; 30 June 2016). The CAP-IT trial results will be published in peer-reviewed journals, and in a report published by the National Institute for Health Research Health Technology Assessment programme. Oral and poster presentations will be given to national and international conferences, and participating families will be notified of the results if they so wish. Key messages will be constructed in partnership with families, and social media will be used in their dissemination. Trial registration number: ISRCTN76888927, EudraCT2016-000809-36.